Start with the exact drug and formulation
GLP-1 medicines do not all have the same interaction advice. Ozempic (semaglutide), Zepbound (tirzepatide), and Foundayo (orforglipron) have product-specific warnings. A general statement that most medicines are “safe to combine” is not a substitute for checking your complete medication list.
Bring prescription medicines, over-the-counter products, vitamins, and supplements to your prescriber or pharmacist for review. Include the name and formulation of your GLP-1 medicine, recent dose changes, and any trouble eating or keeping tablets down.
The information below summarizes prescribing information, not instructions to change treatment. Your prescriber determines your actual dose and medication plan. Do not adjust doses or prescription timing on your own.
Insulin and sulfonylureas: low blood sugar risk
The Ozempic label, section 7.1, Zepbound label, section 7.1, and Foundayo label, section 7.2 warn that use with insulin or an insulin secretagogue such as a sulfonylurea can increase hypoglycemia risk. A prescriber may need to reduce the other medicine's dose.
Ask who will review your glucose readings and what to do if you have low readings or symptoms. Do not reduce or stop insulin yourself. Severe confusion, a seizure, or loss of consciousness needs emergency help.
Birth control pills: the warnings differ
| Product covered by the cited label | Label guidance for oral hormonal contraception |
|---|---|
| Zepbound (tirzepatide) | Switch to a non-oral contraceptive method or add a barrier method for 4 weeks after starting and for 4 weeks after each dose increase. |
| Foundayo (orforglipron) | Switch to a non-oral contraceptive method or add a barrier method for 30 days after starting and for 30 days after each dose increase. |
| Ozempic (injectable semaglutide) | The label does not give those same temporary backup intervals. Its pharmacology studies did not show a clinically relevant interaction with the studied oral contraceptive. This is not a guarantee for every medicine or circumstance. |
These distinctions come from Zepbound sections 7.2 and 8.3, Foundayo sections 7.3 and 8.3, and Ozempic sections 7.2 and 12.3. Do not apply one product's interval to every GLP-1. Vomiting, diarrhea, or missed pills can require separate advice under your contraceptive's own instructions. See GLP-1 medicines and birth control.
Drugs that interact with Foundayo
Foundayo's prescribing information includes interactions beyond delayed stomach emptying. Sections 7.1–7.3 identify the following issues for the prescriber or pharmacist:
| Medicine group | What the label says |
|---|---|
| Strong CYP3A4 inhibitors | The label limits the Foundayo dose when used together. Strong inhibitors that also inhibit OATP1B, such as ritonavir, should be avoided with Foundayo. |
| Strong CYP3A4 inducers | Concomitant use should be avoided because they can reduce Foundayo exposure and effectiveness. |
| Moderate CYP3A4 inducers | The prescriber should monitor effectiveness and may need to adjust treatment. |
| Simvastatin | The label caps simvastatin at 20 mg once daily when used with Foundayo because exposure to its active metabolite increases. This is a prescribing limit, not advice to change your own statin dose. |
| Oral hormonal contraceptives | The 30-day precautions above apply after initiation and each dose increase. |
Ask for a medication review before starting a new antibiotic, antiviral, or other medicine. Do not assume that separating tablets by a few hours resolves an enzyme-related interaction.
Other oral medicines and supplements
Delayed gastric emptying can affect absorption of oral medicines. Zepbound's label specifically advises monitoring medicines that depend on threshold concentrations for efficacy or have a narrow therapeutic index, such as warfarin. The monitoring plan belongs to the prescriber.
There is no single spacing rule for every tablet and every GLP-1 formulation. Oral and injectable formulations can have different administration instructions. Follow the leaflet for the exact product and ask a pharmacist to reconcile any conflicting directions.
Vitamins do not automatically need to be separated from a weekly injection. Supplements can still have interactions or duplicate nutrients; bring them to the review rather than adding them by default. For antibiotic-specific questions, use our GLP-1 and antibiotics guide alongside advice on the actual drug prescribed.
Duplicate treatment and planned procedures
The Zepbound and Foundayo labels do not recommend coadministration with other GLP-1 receptor agonists. Zepbound also should not be coadministered with another tirzepatide-containing product. Switching medicines requires a prescriber-directed plan, not overlapping doses on your own.
Tell the anesthesia or procedure team that you take a GLP-1 medicine before surgery or deep sedation. Delayed gastric emptying creates a separate procedural concern. Do not decide when to stop or restart treatment based on a general interaction chart; ask the team handling your procedure.
Medication-review checklist
- Confirm the exact product, formulation, and most recent dose change.
- Ask whether glucose checks, INR tests, or other monitoring need to change.
- Review contraception before starting or increasing a medicine with a pill-absorption warning.
- Report vomiting, diarrhea, dizziness, or problems keeping medicines down.
- Ask which symptoms need urgent care and who to call about a new prescription.
For a structured pass over the medicines and supplements on your list, the interaction checker pairs a selected GLP-1 medication with other drugs and labels each result by severity. It reports general information and does not replace a pharmacist's review of your full list.
This article is educational and is not a complete interaction checker or personal medical advice. Sources are the manufacturer-hosted prescribing information linked above, accessed September 13, 2026.
